Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripartum cardiomyopathy.

H Ardehali1, E K Kasper, K L Baughman

  • 1Division of Cardiology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA.

Minerva Cardioangiologica
|March 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matrix metalloproteinase 9/neutrophil gelatinase associated lipocalin/tissue inhibitor of metalloproteinasess type 1 complexes are localized within cardiomyocytes and serve as a reservoir of active metalloproteinase in porcine female myocardium.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2014
Same author

Chronic active myocarditis following acute Bartonella henselae infection (cat scratch disease).

The American journal of surgical pathology·2001
Same author

Coagulation markers predicting cardiac transplant rejection.

Transplantation·2001
Same author

Fatal disseminated adenoviral infection in a renal transplant patient.

Transplantation·2001
Same author

Exercise increases hexokinase II mRNA, but not activity in obesity and type 2 diabetes.

Metabolism: clinical and experimental·2001
Same author

Risks of repeat pregnancy after peripartum cardiomyopathy: double jeopardy.

Journal of cardiac failure·2001
Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020
Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020
Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020
Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020
Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020
Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020
See all related articles

Peripartum cardiomyopathy (PPCM) is a rare heart failure affecting women late in pregnancy or postpartum. Early diagnosis and tailored treatment based on heart function are crucial for managing this life-threatening condition.

Area of Science:

  • Cardiology
  • Obstetrics
  • Maternal Health

Background:

  • Peripartum cardiomyopathy (PPCM) is a rare, life-threatening heart condition of unknown cause.
  • It affects previously healthy women during late pregnancy or within five months postpartum.
  • Diagnosis requires congestive heart failure (CHF) and reduced left ventricular systolic function, excluding other cardiac dysfunction causes.

Purpose of the Study:

  • To define diagnostic criteria for PPCM.
  • To outline treatment strategies based on patient prognosis and heart function.
  • To discuss potential interventions for non-recovering patients.

Main Methods:

  • Diagnosis involves clinical presentation of CHF and echocardiographic assessment of left ventricular systolic function.

Related Experiment Videos

  • Treatment is stratified based on resting and exertional cardiac performance.
  • Evaluation for myocarditis is recommended if symptoms persist beyond two weeks.

    • Main Results:

    • Patients with normal cardiac function at rest and with exertion have a good prognosis and can taper medical therapy over 6-12 months.
    • Those with normal resting but abnormal exertional function require long-term treatment with ACE inhibitors or beta-blockers.
    • Patients with persistent depressed LV function have a poor prognosis, necessitating lifelong medication.

    Conclusions:

    • PPCM management requires individualized treatment plans based on cardiac function and prognosis.
    • Pharmacological therapy includes ACE inhibitors (post-delivery), beta-blockers, diuretics, digoxin, and anticoagulation.
    • Advanced therapies like mechanical support or cardiac transplantation may be necessary for refractory cases.